Uchiyama Kiyotaka, Shibagaki Keigo, Yanai Akane, Kusahana Ei, Nakayama Takashin, Morimoto Kohkichi, Washida Naoki, Itoh Hiroshi
Division of Endocrinology, Metabolism and Nephrology Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Shibagaki Dialysis Clinic Jiyugaoka, Tokyo, Japan.
Hypertens Res. 2021 Nov;44(11):1417-1427. doi: 10.1038/s41440-021-00714-1. Epub 2021 Jul 30.
The risk factors for intradialytic systolic blood pressure decline remain poorly understood. We aimed to identify clinical and laboratory predictors of the intradialytic systolic blood pressure decline, considering its seasonal variation. In a retrospective cohort of 47,219 hemodialysis sessions of 307 patients undergoing hemodialysis over one year in three dialysis clinics, the seasonal variation and the predictors of intradialytic systolic blood pressure decline (predialysis systolic blood pressure--nadir intradialytic systolic blood pressure) were assessed using cosinor analysis and linear mixed models adjusted for baseline or monthly hemodialysis-related variables, respectively. The intradialytic systolic blood pressure decline was greatest and least in the winter and summer, respectively, showing a clear seasonal pattern. In both models adjusted for baseline and monthly hemodialysis-related parameters, calcium channel blocker use was associated with a smaller decline (-4.58 [95% confidence interval (CI), -5.84 to -3.33], P < 0.001; -3.66 [95% CI, -5.69 to -1.64], P < 0.001) and α blocker use, with a greater decline (3.25 [95% CI, 1.53-4.97], P < 0.001; 3.57 [95% CI, 1.08-6.06], P = 0.005). Baseline and monthly serum phosphorus levels were positively correlated with the decline (1.55 [95% CI, 0.30-2.80], P = 0.02; 0.59 [95% CI, 0.16-1.00], P = 0.007), and baseline and monthly normalized protein catabolic rates were inversely correlated (respectively, -22.41 [95% CI, -33.53 to -11.28], P < 0.001; 9.65 [95% CI, 4.60-14.70], P < 0.001). In conclusion, calcium channel blocker use, α blocker avoidance, and serum phosphorus-lowering therapy may attenuate the intradialytic systolic blood pressure decline and should be investigated in prospective trials.
透析期间收缩压下降的危险因素仍未得到充分了解。我们旨在确定透析期间收缩压下降的临床和实验室预测因素,并考虑其季节性变化。在三家透析诊所对307例接受血液透析的患者进行的为期一年的47219次血液透析治疗的回顾性队列研究中,分别使用余弦分析和针对基线或每月血液透析相关变量进行调整的线性混合模型,评估透析期间收缩压下降(透析前收缩压 - 透析期间最低收缩压)的季节性变化和预测因素。透析期间收缩压下降在冬季最大,在夏季最小,呈现出明显的季节性模式。在针对基线和每月血液透析相关参数进行调整的两个模型中,使用钙通道阻滞剂与较小的下降幅度相关(-4.58 [95%置信区间(CI),-5.84至-3.33],P < 0.001;-3.66 [95% CI,-5.69至-1.64],P < 0.001),而使用α受体阻滞剂则与较大的下降幅度相关(3.25 [95% CI,1.53 - 4.97],P < 0.001;3.57 [95% CI,1.08 - 6.06],P = 0.005)。基线和每月血清磷水平与下降幅度呈正相关(1.55 [95% CI,0.30 - 2.80],P = 0.02;0.59 [95% CI,0.16 - 1.00],P = 0.007),而基线和每月标准化蛋白分解代谢率呈负相关(分别为-22.41 [95% CI,-33.53至-11.28],P < 0.001;9.65 [95% CI,4.60 - 14.70],P < 0.001)。总之,使用钙通道阻滞剂、避免使用α受体阻滞剂以及降低血清磷的治疗可能会减轻透析期间收缩压的下降,应在前瞻性试验中进行研究。